Effect of spironolactone versus placebo on reducing the risk of atrial fibrillation in patients undergoing coronary artery bypass graft

Phase 2

Recruiting

• Conditions: Atrial fibrillation.; Unspecified atrial fibrillation; I48.91

• Registration Number: IRCT20120215009014N281
• Lead Sponsor: Hamedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 August 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

Age of 18 to 65 years
Candidate for coronary artery bypass graft
Ejection fraction more than 30%

Exclusion Criteria

Presence of background AF rhythm before the intervention
Sensitivity to spironolactone
Using amiodarone in the past three months

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Assessing the risk of atrial fibrillation. Timepoint: 2 weeks after the intervention. Method of measurement: With electrocardiography.;Assessing the ejection fraction. Timepoint: 2 weeks after the intervention. Method of measurement: With echocardiography.